Biomarker driven clinical trials

Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELLE-2 trial results

Survival outcomes from the CALGB 40603 study in triple-negative breast cancer

TH3RESA: T-DM1 improves overall survival in previously treated advanced cancer patients

Molecular evolution of breast cancer during neoadjuvant chemotherapy

NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancer

HER2 status as predictive marker for aromatase inhibitor versus tamoxifen use in early breast cancer

Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cance

Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy

Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study

ER and FGFR1 interaction critical in endocrine resistant breast cancer

Interrupting breast cancer treatment for young women who desire pregnancy

Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging

Novel estrogen receptor-targeting agent represents ‘quantum leap’

Ductal carcinoma in situ: Anastrozole versus tamoxifen

Update on management of the axilla

Higher local recurrence after skin-sparing than simple mastectomy for DCIS

Peri-operative lapatinib has profound antiproliferative effect in early breast cancer

Guidelines and management of advanced breast cancer in limited resource settings

New developments and technologies in hereditary cancer

Results of the CREATE-X trial

Hormonal treatments produce similar quality of life outcomes in DCIS

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen

Treating women with endocrine-resistant HR /HER2 advanced breast cancer

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen

Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen both groups reported similar quality of life

Estrogen receptor mutations detected in plasma associated with worse overall survival in metastatic breast cancer

Improved survival outcomes in women with HER2-negative breast cancer after neoadjuvant chemotherapy

Breast-conserving therapy yields better 10-year outcomes than mastectomy for early-stage patients

Adding carboplatin to presurgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer

Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation

Analysis of blood samples finds ESR1 gene mutations are prevalent and associated with worse overall survival

Breast-conserving therapy yielded better outcomes than mastectomy for early-stage patients

Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation

Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3B

Denosumab improves disease-free survival for postmenopausal patients with HR-positive breast cancer

Test to identity which breast cancer patients will respond to platinum-based chemotherapy

Overexpression of the enzyme APOBEC3B is linked to somatic mutagenesis in breast and other cancers

Women with luminal A breast cancer subtype do not seem to benefit from adjuvant chemotherapy

Denosumab improves disease-free survival for postmenopausal HR-positive breast cancer

Women with luminal A subtype of breast cancer did not benefit from adjuvant chemotherapy

Pathologic complete response to presurgery chemo improves survival for triple-negative breast cancer